Literature DB >> 19556827

Association of TNFA -308 G/A and TNFRI +36 A/G gene polymorphisms with glaucoma.

Mohammad Reza Razeghinejad1, Feisal Rahat, Eskandar Kamali-Sarvestani.   

Abstract

OBJECTIVE: TNF-alpha is one of the most important factors recognized in the pathogenesis of open-angle glaucoma. Therefore, the association of single nucleotide polymorphisms in the TNFRI gene and the promoter region of the TNFA gene with glaucoma susceptibility was investigated in the present study.
METHOD: In total, 223 patients with glaucoma and 202 unrelated controls were genotyped by allele-specific oligonucleotide PCR and PCR- restriction fragment length polymorphism to determine TNFA -308 G/A and TNFRI +36 A/G polymorphisms, respectively.
RESULTS: In contrast to TNFRI polymorphisms, the genotypes of TNFA -308 G/A polymorphisms showed a significant difference between patients and controls (p = 0.0025). Of interest, the distribution of TNFA genotypes was significantly different between patients with primary open-angle glaucoma (p = 0.001) or pseudoexfoliative glaucoma (p = 0.001) and controls, while no difference was found when chronic angle-closure glaucoma patients were compared to controls (p = 0.72).
CONCLUSION: In line with studies showing the role of TNF-alpha in open-angle glaucoma, the results of the present study showed that inheritance of the high producer TNFA -308 A allele might be a susceptibility factor for the development of open-angle glaucoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556827     DOI: 10.1159/000226108

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  16 in total

1.  Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population.

Authors:  Muhammad Imran Khan; Shazia Micheal; Noreen Rana; Farah Akhtar; Anneke I den Hollander; Asifa Ahmed; Raheel Qamar
Journal:  Mol Vis       Date:  2009-12-22       Impact factor: 2.367

2.  A nested case control study of plasma ICAM-1, E-selectin and TNF receptor 2 levels, and incident primary open-angle glaucoma.

Authors:  Jae H Kang; Janey L Wiggs; Louis R Pasquale
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-11       Impact factor: 4.799

Review 3.  Genetics of primary open angle glaucoma.

Authors:  Mitsuko Takamoto; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-11-21       Impact factor: 2.447

4.  Genes of tumor necrosis factors and their receptors and the primary open angle glaucoma in the population of Central Russia.

Authors:  Evgeniya Tikunova; Veronika Ovtcharova; Evgeny Reshetnikov; Volodymyr Dvornyk; Alexey Polonikov; Olga Bushueva; Mikhail Churnosov
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

Review 5.  Genetics of exfoliation syndrome and glaucoma.

Authors:  Inas F Aboobakar; R Rand Allingham
Journal:  Int Ophthalmol Clin       Date:  2014

Review 6.  Working your SOCS off: The role of ASB10 and protein degradation pathways in glaucoma.

Authors:  Kate E Keller; Mary K Wirtz
Journal:  Exp Eye Res       Date:  2016-06-11       Impact factor: 3.467

Review 7.  Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha.

Authors:  Renu Agarwal; Puneet Agarwal
Journal:  Indian J Ophthalmol       Date:  2012-07       Impact factor: 1.848

8.  Genetics and genomics of pseudoexfoliation syndrome/glaucoma.

Authors:  Ursula Schlötzer-Schrehardt
Journal:  Middle East Afr J Ophthalmol       Date:  2011-01

Review 9.  Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations.

Authors:  Eman Elhawy; Gautam Kamthan; Cecilia Q Dong; John Danias
Journal:  Hum Genomics       Date:  2012-10-10       Impact factor: 4.639

10.  Roles of tumor necrosis factor alpha gene polymorphisms, tumor necrosis factor alpha level in aqueous humor, and the risks of open angle glaucoma: a meta-analysis.

Authors:  Xiangyang Xin; Lili Gao; Tong Wu; Fengyuan Sun
Journal:  Mol Vis       Date:  2013-02-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.